Four months after the Committee for Medicinal Products for Human Use (CHMP) rejected Apellis’ GA application for Syfovre for a second time, Astellas has withdrawn its application for the ...
Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by ...
Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...
a large Medicare Advantage plan will make SYFOVRE the only preferred product on its formulary. Received a negative opinion from the Committee for Medicinal Products for Human Use (CHMP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback